Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
Background The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly controlled T2DM patients with drug-naïve or metformin failure. Methods In this three-arm, multicenter, open-label, randomized, controlled trial, poorly controlled T2DM patients were randomized to receive GLIM (n=35), ALO (n=31), or ALO-PIO (n=33) therapy for 24 weeks. The primary endpoint was change in the mean glycosylated hemoglobin (HbA1c) levels at week 24 from baseline. Secondary endpoints were changes in HbA1c level at week 12 from baseline, fasting plasma glucose (FPG) levels, lipid profiles at weeks 12 and 24, and parameters of glycemic variability, assessed by continuous glucose monitoring for 24 weeks. Results At weeks 12 and 24, the ALO-PIO group showed significant reduction in HbA1c levels compared to the ALO group (–0.96%±0.17% vs. –0.37%±0.17% at week 12; –1.13%±0.19% vs. –0.18%±0.2% at week 24). The ALO-PIO therapy caused greater reduction in FPG levels and significant increase in high-density lipoprotein cholesterol levels at weeks 12 and 24 than the ALO therapy. Compared to low-dose GLIM therapy, ALO-PIO therapy showed greater improvement in glycemic variability. The adverse events were similar among the three arms. Conclusion ALO-PIO combination therapy during the early period exerts better glycemic control than ALO monotherapy and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-naïve or metformin failed T2DM patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Diabetes & Metabolism Journal - 46(2022), 5, Seite 689-700 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hae Jin Kim [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Alogliptin |
|---|
| doi: |
10.4093/dmj.2021.0183 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ00887462X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ00887462X | ||
| 003 | DE-627 | ||
| 005 | 20230503113144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4093/dmj.2021.0183 |2 doi | |
| 035 | |a (DE-627)DOAJ00887462X | ||
| 035 | |a (DE-599)DOAJe82396ec1d0c4143a0356bf405815c2f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Hae Jin Kim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly controlled T2DM patients with drug-naïve or metformin failure. Methods In this three-arm, multicenter, open-label, randomized, controlled trial, poorly controlled T2DM patients were randomized to receive GLIM (n=35), ALO (n=31), or ALO-PIO (n=33) therapy for 24 weeks. The primary endpoint was change in the mean glycosylated hemoglobin (HbA1c) levels at week 24 from baseline. Secondary endpoints were changes in HbA1c level at week 12 from baseline, fasting plasma glucose (FPG) levels, lipid profiles at weeks 12 and 24, and parameters of glycemic variability, assessed by continuous glucose monitoring for 24 weeks. Results At weeks 12 and 24, the ALO-PIO group showed significant reduction in HbA1c levels compared to the ALO group (–0.96%±0.17% vs. –0.37%±0.17% at week 12; –1.13%±0.19% vs. –0.18%±0.2% at week 24). The ALO-PIO therapy caused greater reduction in FPG levels and significant increase in high-density lipoprotein cholesterol levels at weeks 12 and 24 than the ALO therapy. Compared to low-dose GLIM therapy, ALO-PIO therapy showed greater improvement in glycemic variability. The adverse events were similar among the three arms. Conclusion ALO-PIO combination therapy during the early period exerts better glycemic control than ALO monotherapy and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-naïve or metformin failed T2DM patients. | ||
| 650 | 4 | |a alogliptin | |
| 650 | 4 | |a diabetes mellitus, type 2 | |
| 650 | 4 | |a glimepiride | |
| 650 | 4 | |a glycemic control | |
| 650 | 4 | |a pioglitazone | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a In Kyung Jeong |e verfasserin |4 aut | |
| 700 | 0 | |a Kyu Yeon Hur |e verfasserin |4 aut | |
| 700 | 0 | |a Soo-Kyung Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Jung Hyun Noh |e verfasserin |4 aut | |
| 700 | 0 | |a Sung Wan Chun |e verfasserin |4 aut | |
| 700 | 0 | |a Eun Seok Kang |e verfasserin |4 aut | |
| 700 | 0 | |a Eun-Jung Rhee |e verfasserin |4 aut | |
| 700 | 0 | |a Sung Hee Choi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Diabetes & Metabolism Journal |d Korean Diabetes Association, 2016 |g 46(2022), 5, Seite 689-700 |w (DE-627)DOAJ00014374X |x 22336087 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2022 |g number:5 |g pages:689-700 |
| 856 | 4 | 0 | |u https://doi.org/10.4093/dmj.2021.0183 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e82396ec1d0c4143a0356bf405815c2f |z kostenfrei |
| 856 | 4 | 0 | |u http://e-dmj.org/upload/pdf/dmj-2021-0183.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2233-6079 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2233-6087 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2022 |e 5 |h 689-700 | ||